PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
111.14%
Revenue growth 1.25-1.5x CRON.TO's 100.00%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
91.08%
Gross profit growth above 1.5x CRON.TO's 51.93%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
10.33%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
10.33%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
10.46%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
10.98%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
10.98%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-1.98%
Share reduction while CRON.TO is at 1.29%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.00%
Diluted share reduction more than 1.5x CRON.TO's 1.29%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
48.20%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
11.57%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-109.58%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-109.58%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-888.70%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-9.81%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-9.81%
Negative 5Y net income/share CAGR while CRON.TO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-28.19%
Negative 3Y CAGR while CRON.TO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
19.21%
Equity/share CAGR of 19.21% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
19.21%
Equity/share CAGR of 19.21% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
135.88%
Equity/share CAGR of 135.88% while CRON.TO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.20%
AR growth of 24.20% while CRON.TO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-2.65%
Inventory is declining while CRON.TO stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.88%
Negative asset growth while CRON.TO invests at 13.54%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.13%
We have a declining book value while CRON.TO shows 35.07%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-37.31%
Our R&D shrinks while CRON.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
53.56%
SG&A growth well above CRON.TO's 23.90%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.